2.11 +0.09 (4.02%)
CERS
Stock Details
Last Trade:2.11 Change:+0.09 (4.02%) Prev Close:2.02 Open: 2.24 Days Range:2.10 – 2.26 52 Week Range: 0.59 - 3.57 Volume:885712 P/E: N/AEPS:-0.76
View AllRecent Alerts 02/10/10
Recent Alert on 02/09/10 at 8:45am
Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
Cerus Corporation (NASDAQ: CERS) announced today that it has entered into a collaborative agreement with France's national transfusion service, the Etablissement Francais du Sang (EFS), for the development of the company's INTERCEPT Blood System for... Read More
Recent Alert on 02/09/10 at 8:45am
Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
Recent Alert on 01/14/10 at 10:17am
Morning Movers 01/14: ETRM, LAB, TSTR, CROX, HEB Higher; ROSG, MRNA, IPII, MED Lower
Morning Movers 01/14: ETRM, LAB, TSTR, CROX, HEB Higher; ROSG, MRNA, IPII, MED Lower
Recent Alert on 11/16/09 at 2:21pm
Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
Recent Alert on 11/16/09 at 2:21pm
Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
Cerus (CERS) Halted As FDA To Review Proposed Phase III Clinical Trial Design for the INTERCEPT Blood System
View AllRecent Press Releases
Press Release on 02/09/10 at 8:30am
Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development
Cerus to Collaborate with French National Transfusion Service on INTERCEPT Red Blood Cell Development
Press Release on 02/08/10 at 8:49pm
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
Cerus Corporation Reports Positive Outcome of Phase 1 Clinical Trial of INTERCEPT Red Blood Cells
View AllRecent SEC Filings
View AllRecent Blog Posts
Blog Posts on 08/19/09 at 4:31pm
Closing Update for Wednesday, August 19: Stocks (and Crude) Scratch Back
Closing Update for Wednesday, August 19: Stocks (and Crude) Scratch Back

